RRAGC: Metabolites of Glucose and Potential Drug Targets (G64121)

Target Name: RRAGC

NCBI ID: G64121

RRAGC

RRAGC: Metabolites of Glucose and Potential Drug Targets

RRAGC (Researched and Regulated Advanced Glycation product) are a group of metabolites that are generated from glucose during cellular metabolism. These molecules have been observed to be involved in a wide range of cellular processes, including inflammation, cellular signaling, and cell death. As As a result, RRAGC have become a focus of research in the field of diseases, including diabetes.

One of the key features of RRAGC is their ability to interact with proteins, including those involved in the immune response and inflammation. These interactions can result in the formation of immune complexes, which are dangerous aggregates of antibodies that can cause damage to tissues and organs . Chronic inflammation, as seen in diseases such as diabetes and cardiovascular disease, is thought to be a result of the failure of the immune system to remove these immune complexes.

RRAGC have also been shown to play a role in cellular signaling, particularly in the regulation of cell death. In addition, they have been linked to the development and progression of a wide range of diseases, including neurodegenerative disorders, cancer, and cardiovascular disease.

The potential implications of RRAGC as drug targets or biomarkers are significant. RRAGC have been shown to be involved in a wide range of cellular processes, including inflammation, cellular signaling, and cell death. As a result, they may be useful in the development of new treatments for a variety of diseases.

One potential approach to targeting RRAGC is through the use of small molecules, such as drugs that can modulate the activity of enzymes involved in their metabolism. These molecules have been shown to be effective in reducing the levels of RRAGC in cells, and may be useful in the treatment of diseases caused by chronic inflammation or cellular signaling dysfunction.

Another approach to targeting RRAGC is through the use of antibodies that can specifically recognize and bind to them. These antibodies have been shown to be effective in reducing the levels of RRAGC in cells, and may be useful in the treatment of diseases caused by chronic inflammation or cellular signaling dysfunction.

In addition to their potential use as drug targets or biomarkers, RRAGC also have implications for the development of new diagnostic tests. The formation of immune complexes, as seen in diseases such as diabetes and cardiovascular disease, is thought to be a result of the failure of the immune system to remove these immune complexes. As such, the detection of RRAGC in cells or fluids may be a useful diagnostic test for a variety of diseases.

Overall, the research on RRAGC is still in its early stages, but the potential implications of these molecules as drug targets or biomarkers, as well as their potential as diagnostic tools, are significant. Further research is needed to fully understand the role of RRAGC in disease and to develop effective treatments.

Protein Name: Ras Related GTP Binding C

Functions: Guanine nucleotide-binding protein that plays a crucial role in the cellular response to amino acid availability through regulation of the mTORC1 signaling cascade (PubMed:20381137, PubMed:27234373, PubMed:24095279). Forms heterodimeric Rag complexes with RRAGA or RRAGB and cycles between an inactive GTP-bound and an active GDP-bound form (PubMed:24095279, PubMed:32868926). In its active form participates in the relocalization of mTORC1 to the lysosomes and its subsequent activation by the GTPase RHEB (PubMed:20381137, PubMed:27234373, PubMed:24095279). This is a crucial step in the activation of the TOR signaling cascade by amino acids (PubMed:20381137, PubMed:27234373, PubMed:24095279)

The "RRAGC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RRAGC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets